A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia. Sawa M, Miyamoto T, Kim HJ, Hiramatsu Y, et al. Int J Hematol 2025;121:56-67.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sawa M, Miyamoto T, Kim HJ, Hiramatsu Y, et al. A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia. Int J Hematol 2025;121:56-67.
PMID: 39503987